The predictive value of transaminases at admission in patients hospitalized for heart failure: Findings from the RO-AHFS registry

European Heart Journal: Acute Cardiovascular Care

Volumn 2, Issue 2, 2013, Pages 99-108

  Ambrosy, Andrew P ^a   Gheorghiade, Mihai ^b   Bubenek, Serban ^c   Vinereanu, Dragos ^d   Vaduganathan, Muthiah ^e   Macarie, Cezar ^c   Chioncel, Ovidiu ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c CC Iliescu Institute for Cardiovascular Disease   (Romania)

^d Universitary Emergency Hospital   (Romania)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alanine transaminase; aspartate transaminase; hospitalization; mortality

Indexed keywords

ALANINE TRANSAMINASE; ASPARTATE TRANSAMINASE; HOSPITALIZATION; MORTALITY;

AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; CARDIOTONIC AGENTS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; MALE; PATIENT ADMISSION; PREDICTIVE VALUE OF TESTS; ROC CURVE;

EID: 84901418107     PISSN: 20488726     EISSN: 20488734     Source Type: Journal    
DOI: 10.1177/2048872612474906     Document Type: Article

References (25)

1. van Deursen VM, Damman K, Hillege HL, et al. Abnormal liver function in relation to hemodynamic profile in heart failure patients. J Card Fail 2010; 16: 84–90.
2. Shinagawa H, Inomata T, Koitabashi T, et al. Prognostic significance of increased serum bilirubin levels coincident with cardiac decompensation in chronic heart failure. Circ J 2008; 72: 364–369.
3. Ambrosy AP, Vaduganathan M, Huffman MD, et al. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. Eur J Heart Fail 2012; 14: 302–311.
4. Batin P, Wickens M, McEntegart D, et al. The importance of abnormalities of liver function tests in predicting mortality in chronic heart failure. Eur Heart J 1995; 16: 1613–1618.
5. Allen LA, Felker GM, Pocock S, et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail 2009; 11: 170–177.
6. Felder L, Mund A and Parker JG. Liver function tests in chronic congestive heart failure. Circulation 1950; 2: 286–297.
7. Jolliffe N. Liver function in congestive heart failure. J Clin Invest 1930; 8: 419–433.
8. Richman SM, Delman AJ and Grob D. Alterations in indices of liver function in congestive heart failure with particular reference to serum enzymes. Am J Med 1961; 30: 211–225.
9. Sherlock S. The liver in heart failure; relation of anatomical, functional, and circulatory changes. Br Heart J 1951; 13: 273–293.
10. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: 1977–2016.
11. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388–2442.
12. Chioncel O, Vinereanu D, Datcu M, et al. The Romanian Acute Heart Failure Syndromes (RO-AHFS) registry. Am Heart J 2011; 162: 142–453, e1.
13. Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 384–416.
14. Pratt DS and Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Eng J Med 2000; 342: 1266–1271.
15. Giboney PT. Mildly elevated liver transaminase levels in the asymptomatic patient. Am Fam Physician 2005; 71: 1105–1110.
16. Gheorghiade M, Orlandi C, Burnett JC, et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail 2005; 11: 260–269.
17. Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA 2007; 297: 1332–1343.
18. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 2007; 297: 1319–1331.
19. Nardone A, Anastassopoulou CG, Theeten H, et al. A comparison of hepatitis B seroepidemiology in ten European countries. Epidemiol Infect 2009; 137: 961–969.
20. Gheorghe L, Iacob S and Csiki IE. Prevalence of hepatitis C in Romania: different from European rates? J Hepatol 2008; 49: 661–662, author reply.
21. McKenney JM, Davidson MH, Jacobson TA, et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006; 97: 89C–94C.
22. Cohen DE, Anania FA and Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 2006; 97: 77C–81C.
23. Wang NC, Maggioni AP, Konstam MA, et al. Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA 2008; 299: 2656–2666.
24. Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005; 46: 57–64.
25. Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006; 296: 2217–2226.